Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia
Status:
Unknown status
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate efficacy and safety of fresh frozen plasma(FFP),
high dose methylprednisolone(HDMP) and rituximab for ultra-high risk chronic lymphocytic
leukemia.
Phase:
Phase 3
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University